Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Conditions

Proteus Syndrome 3Neoplasms 2Endometrial Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Lymphoma 1Hereditary Sensory and Autonomic Neuropathies 1Growth Disorders 1Congenital Abnormalities 1

Interventions

Cytarabine 86fludarabine phosphate 85Peripheral Blood Stem Cell Transplantation 76Cyclophosphamide 69Busulfan 63Mycophenolic Acid 51Tacrolimus 48Cyclosporine 48Etoposide 43Whole-Body Irradiation 42Antilymphocyte Serum 40Methotrexate 39Filgrastim 39Flow Cytometry 30Radiotherapy 29Melphalan 24Mitoxantrone 23Daunorubicin 23Idarubicin 21Cord Blood Stem Cell Transplantation 19Polymerase Chain Reaction 17Methylprednisolone 17Gene Expression Profiling 17sargramostim 15Granulocyte Colony-Stimulating Factor 15Clofarabine 15Transplantation 14Decitabine 14Gemtuzumab 13aldesleukin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Congenital Abnormalities × Miransertib × Clear all
NCT03317366 2021-08-06

Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

No longer available

Congenital Abnormalities, Growth Disorders, Hereditary Sensory and Autonomic Neuropathies, Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡